Thaizolidinediones molecule has basic pharmacophore which shows wide range of Pharmacological Activity like Antidiabetic, Anticancer, Antimicrobial, and Anti-inflammatory.
Introduction of new classes of pharmacologic agents 2 sulfonylurea’s, glinides, biguanides, glitazones (thiazolidinediones) and a-glucosidase inhibitors. In this most of the drugs can cause non-compliance, hypoglycemia and obesity. 2, 4-thiazolidinediones are associated with diverse biocidal activities probably by virtue of a toxophoric –N=C-S- grouping. There are evidences of chemical structures of 2, 4-thiazolidinedione when compared to Rosiglitazone which is considered as oral hypoglycemic agents. The thiazolidinediones represent a novel class of hypoglycemic agents for treatment of NIDDM. Thiazolidinediones (TZDs), which are known to sensitize tissues to insulin, have been developed and clinically used as antidiabetic agents. They have been shown to reduce plasma glucose, lipid, and insulin levels, and used for the treatment of type 2 diabetes. Thiazolidinediones substituted with a phenyloxazolyl group,pyridines and purine containing group improve potency and safety. Substituted at the N-activity deminishes the antidiabetic activity. Molecule has wide range of activity future cytotoxic activity research may be give potent molecule.
Cite this article:
Sushil D. Patil. Thaizolidinedione: Oral Insulin Sensitizing Agent. Asian J. Research Chem 7(1): January 2014; Page 103-112.